{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:56:33Z","timestamp":1780775793417,"version":"3.54.1"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cytomegalovirus (CMV) is one of the most frequent opportunistic infections in kidney transplant (KT) recipients and is a risk factor for patient and graft survival after KT. Center-to-center variation, optimal prevention and treatment strategies in pediatric KT are currently unknown. This survey aimed to assess current CMV prevention and treatment strategies used among French pediatric KT centers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A web-based survey was sent to all 13 French pediatric kidney transplantation centers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twelve (92%) centers responded to the survey. All centers used prophylaxis for the donor-positive\/recipient-negative (D+\/R-) group. For R\u2009+\u2009patients, 54% used prophylaxis, 37% used a pre-emptive strategy. In the low-risk group, D-\/R-, 50% used a pre-emptive approach and 50% had no specific prevention strategy. The antiviral used by all centers for prophylaxis was valganciclovir (VGCV). The duration of prophylaxis varied from 3 to 7 months and the duration of viral load monitoring varied from 6 months to indefinitely. No center used a hybrid\/sequential approach. For the treatment of CMV DNAemia, VGCV or intravenous GCV were used. Therapeutic drug monitoring of VGCV was performed in 5 centers (42%). Five centers reported drug resistance. Eight centers (67%) administered VGCV during the treatment of acute graft rejection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There is uniformity in CMV management in some areas among pediatric KT centers in France but not in others which remain diverse and are not up to date with current guidelines, suggesting unnecessary variation which could be reduced with better evidence to inform practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.1057352","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T05:48:20Z","timestamp":1671169700000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["National survey of prevention and management of CMV infection in pediatric kidney transplantation in comparison to clinical practice guidelines"],"prefix":"10.3389","volume":"10","author":[{"given":"Iona","family":"Madden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Baudouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Charbit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Ranchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00eblle","family":"Roussey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentine","family":"Garaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Decramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Fila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Merieau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Vrillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Zaloszyc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Harambat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0b013e3181cee42f","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1097\/TP.0000000000000888","article-title":"Cytomegalovirus infection in pediatric renal transplantation and the impact of chemoprophylaxis with (val-)ganciclovir","volume":"100","author":"H\u00f6cker","year":"2016","journal-title":"Transplantation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.idc.2013.02.005","article-title":"AST Infectious diseases community of practice. Cytomegalovirus in Solid Organ Transplantation","volume":"4","author":"Razonable","year":"2013","journal-title":"Am J Transplant Suppl"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-guidelines of the American society of transplantation infectious diseases community of practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e13369","DOI":"10.1111\/ctr.13369","article-title":"A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients","volume":"32","author":"Shaikh","year":"2018","journal-title":"Clin Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1111\/ajt.12755","article-title":"Current prevention strategies against cytomegalovirus in the studies in pediatric liver transplantation (SPLIT) centers","volume":"14","author":"Danziger-Isakov","year":"2014","journal-title":"Am J Transplant"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and estimation of GFR in children and adolescents","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"B8","doi-asserted-by":"publisher","first-page":"10332","DOI":"10.3389\/ti.2022.10332","article-title":"Cytomegalovirus management in solid organ transplant recipients: a Pre-COVID-19 survey from the working group of the European society for organ transplantation","volume":"35","author":"Grossi","year":"2022","journal-title":"Transpl Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/cid\/ciw084","article-title":"Lessons learned from a randomized study of oral valganciclovir versus parenteral ganciclovir treatment of cytomegalovirus disease in solid organ transplant recipients: the VICTOR trial","volume":"62","author":"\u00c5sberg","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1681\/ASN.2012010100","article-title":"Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation","volume":"23","author":"Reischig","year":"2012","journal-title":"J Am Soc Nephrol JASN"},{"key":"B11","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/petr.12786","article-title":"A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients","volume":"20","author":"Suresh","year":"2016","journal-title":"Pediatr Transplant"},{"key":"B12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/jpids\/pis056","article-title":"Assessment of cytomegalovirus hybrid preventative strategy in pediatric heart transplant patients","volume":"1","author":"Lin","year":"2012","journal-title":"J Pediatr Infect Dis Soc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1097\/TP.0b013e3181a19cda","article-title":"A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients","volume":"87","author":"Madan","year":"2009","journal-title":"Transplantation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1097\/tp.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2174\/1874303X01407010152","article-title":"Efficacy of extended valganciclovir prophylaxis in preventing cytomegalovirus infection in pediatric kidney transplantation","volume":"7","author":"Hashim","year":"2014","journal-title":"Open Urol Nephrol J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/TP.0b013e3181ea3955","article-title":"An international survey of cytomegalovirus management practices in lung transplantation","volume":"90","author":"Zuk","year":"2010","journal-title":"Transplantation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/TP.0000000000000160","article-title":"Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment","volume":"98","author":"Stern","year":"2014","journal-title":"Transplantation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1681\/ASN.2009111188","article-title":"Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation","volume":"21","author":"Smith","year":"2010","journal-title":"J Am Soc Nephrol JASN"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1057352\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T05:48:21Z","timestamp":1671169701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1057352\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":18,"alternative-id":["10.3389\/fped.2022.1057352"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.1057352","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"article-number":"1057352"}}